Declaration of interests SZ reports previous payments to her institution (Monash University) from AstraZeneca, Boehringer Ingelheim, CSL Seqirus, Eli Lilly Australia, GlaxoSmithKline, Moderna, Novo Nordisk, and Sanofi for her participation in advisory boards, steering committees, and educational meetings. DD has consulted for Arrowhead, Eli Lilly and Company, Fractyl, MBX, Proteostasis, Structure, Sun Pharma, and Vertex. IP, DM, HN, XW, GW, and RJW are employees and shareholders of Eli Lilly and Company. DLB discloses participation on advisory boards for AngioWave, Antlia, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, E-Star Biotech, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, NirvaMed, Novo Nordisk, Repair Biotechnologies, Stasys, and Tourmaline Bio; is on the board of directors of the American Heart Association; owns stock options in AngioWave and DRS.LINQ; owns stocks in Bristol Myers Squibb and High Enroll; has served as a consultant for Alnylam, Altimmune, Broadview Ventures, Corcept, Corsera, GlaxoSmithKline, Hims, SERB, SFJ, Summa, and Worldwide Clinical Trials; has served on data monitoring committees for Acesion, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research, Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (ABILITY-DM trial, funded by Concept Medical; ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research Institute, and Rutgers University (for the NIH-funded MINT trial); and has received honoraria from the American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi and Bristol Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Duke Clinical Research Institute, Engage Health Media, HMP Global (Editor in Chief, Journal of Invasive Cardiology), Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Philips (Becker's Webinar on AI), Population Health Research Institute, WebMD (CME steering committees), and Wiley (steering committee); is Deputy Editor of Clinical Cardiology and Progress in Cardiovascular Diseases; is named on a patent for sotagliflozin (assigned to Brigham and Women's Hospital who was assigned to Lexicon; neither he nor Brigham and Women's Hospital receive any income from this patent); reports research funding from 89Bio, Abbott, Acesion, Afimmune, Alnylam, Amarin, Amgen, AstraZeneca, AtriCure, Bayer, Boehringer Ingelheim, Boston Scientific, CellProthera, Cereno Scientific, Chiesi, Cleerly, CSL Behring, Eli Lilly and Company, Faraday, Fractyl, Idorsia, Janssen, Javelin, Lexicon, Medtronic, Merck, MiRUS, Moderna, Novartis, Novo Nordisk, Pfizer, PhaseBio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, and Stasys; has received royalties from Elsevier (Editor, Braunwald's Heart Disease); and is site co-investigator of Cleerly. JBB has received salary support from clinical trial contracts to his employer by Corcept, Dexcom, GentiBio, and Novo Nordisk; is a consultant with personal compensation from Aardvark, Altimmune, Amgen, Antag, Aqua Medical, AstraZeneca, Boehringer Ingelheim, Corcept, Dexcom, Eli Lilly and Company, embecta, GentiBio, Insulet, Metsera, Novo Nordisk, Tandem, Vertex, and Zealand; and has stock or stock options in Glyscend, Mellitus Health, Metsera, Pendulum, Praetego, and Stability Health. SDP has served as advisor for Abbott, Applied Therapeutics, Biomea Fusion, Eli Lilly and Company, Menarini, Novo Nordisk, Roche, and Sun Pharma; has received fees for speaking from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Laboratori Guidotti, Menarini, and Novo Nordisk; has served as past president of the European Association for the Study of Diabetes; and is currently president of the European Diabetes Forum and the Menarini Foundation. FG reports grants from Eli Lilly and Company and Roche Diabetes Care; consulting fees from Eli Lilly and Company and Novo Nordisk; support for attending meetings or travel from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, LifeScan, Medtronic, Merck Sharp & Dohme, Novo Nordisk, Roche Diabetes Care, and Sanofi Aventis; participation on advisory boards for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, LifeScan, MedImmune, Medtronic, Merck Sharp & Dohme, Novo Nordisk, Roche Diabetes Care, and Sanofi Aventis; and unpaid leadership roles for the European Association for the Study of Diabetes and European Foundation for the Study of Diabetes. SEK has received grant support from Corcept; and consulted for AltPep, Amgen, Biomea, Congruence, Eli Lilly and Company, Merck, Neurimmune, and Novo Nordisk; and is a stockholder for Altpep. MK has received consulting fees from Abbott, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Merck Sharp & Dohme, Novo Nordisk, and Sanofi; and honoraria for speakers’ bureaus and educational events from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, MedLearning, Merck Sharpe & Dohme, Novartis, Novo Nordisk, PeerView, and SCIARC. AML has received honoraria for consultancy from Alnylam, Amgen, Ardelyx, Brainstorm Cell, Cadrenal, Capricor, Eli Lilly and Company, Johnson & Johnson, Medtronic, Neovasc, Novo Nordisk, ReCor, TD Cowen, and V-Wave; and has received research funding paid to his institution from AbbVie, AstraZeneca, CSL Behring, Eli Lilly and Company, Esperion, and Novartis. DKM has received consulting fees from Alveus, Amgen, Boehringer Ingelheim, CSL Behring, Kailera, Lexicon, Lilly USA, Metsera, New Amsterdam, Neurotronics, Novo Nordisk, and Zealand. MAN has been a member on advisory boards or has consulted for Boehringer Ingelheim, Eli Lilly and Company, Medtronic, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Regor, Sun Pharma, and Structure (ShouTi, Gasherbrum); has received grant support from Merck Sharp & Dohme; has served on the speakers bureau of Eli Lilly and Company, Medical Learning Institute, Medscape, Merck Sharp & Dohme, and Novo Nordisk; and is on a data monitoring and safety board for Inventiva. SEN reports that his institution, the Cleveland Clinic Center for Clinical Research (C5Research) has received funding to perform clinical trials from AbbVie, Amgen, Arrowhead, AstraZeneca, Bristol Myers Squibb, Kardigan, CRISPR Therapeutics, Eli Lilly and Company, Esperion, Medtronic, MyoKardia, New Amsterdam, Novartis, Pfizer, and Silence. SEN is involved in conducting these clinical trials but receives no personal remuneration for his participation. SEN consults for these pharmaceutical companies but does not accept compensation. NS has consulted for or received speaker honoraria, or both, from Abbott, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot, Eli Lilly and Company, GlaxoSmithKline, Hanmi, Menarini-Ricerche, Metsera, Novartis, Novo Nordisk, Pfizer, and Roche; and received grant support paid to his university from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche, outside the submitted work. BZ reports being a consultant for Eli Lilly and Company. AC has received payments for his participation in advisory boards, steering committees, and educational meetings from Abbott, Bayer, Berlin Chemie, Boehringer Ingelheim, Cipla, Eli Lilly and Company, Guidotti, Hikamar, Merck, Merck Sharpe & Dohme, Novo Nordisk, Sanofi, Servier, and Sun Pharma. LS reports payments for participation in lectures from Eli Lilly and Company and Novo Nordisk. AV reports previous payments from Amgen, Amarin, Daiichi Sankyo, Eli Lilly and Company, Merck Sharpe & Dohme, Novartis, Novo Nordisk, Pfizer, and Sanofi for her participation in advisory boards and educational meetings. JCB and RW are academic statisticians employed by Monash University. SJN received grant and research support from AstraZeneca, New Amsterdam, Amgen, Anthera, Cerenis, Cyclarity, Eli Lilly and Company, Esperion, InfraReDx, LipoScience, The Medicines Company, Novartis, Resverlogix, Roche, and Sanofi-Regeneron; and was a consultant for Abcentra, Akcea, Amarin, Anthera, AstraZeneca, Boehringer Ingelheim, CSL Behring, CSL Seqirus, Daiichi Sankyo, Eli Lilly and Company, Esperion, Merck, Omthera, Resverlogix, Sanofi-Regeneron, Scribe, Silence, Takeda, and Vaxxinity. All other authors declare no competing interests.
PubMed
